The effects of oxprenolol (Trasicor, Ciba 39089-Ba) on patterns of urinary sodium excretion in man.
D000433:1-Propanol / Q000008:administration & dosage / Q000494:pharmacology*; D000319:Adrenergic beta-Antagonists / Q000494:pharmacology; D000328:Adult; D000605:Amino Alcohols / Q000008:administration & dosage / Q000494:pharmacology*; D002312:Cardiomyopathy, Hypertrophic / Q000652:urine; D002940:Circadian Rhythm; D002986:Clinical Trials as Topic; D003327:Coronary Disease / Q000652:urine; D004374:Ductus Arteriosus, Patent / Q000652:urine; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011433:Propranolol / Q000494:pharmacology; D011437:Propylamines / Q000008:administration & dosage / Q000494:pharmacology; D012214:Rheumatic Heart Disease / Q000652:urine; D012964:Sodium / Q000652:urine*
D000319:Adrenergic beta-Antagonists; D000605:Amino Alcohols; D011437:Propylamines; D000433:1-Propanol; D012964:Sodium; D011433:Propranolol